Inovio Prices $75M Offering at $1.05, a 28% Discount to Last Sale, Days After First FDA Approval
INO has more than doubled off its 52-week low of $0.563 on elevated volume (3.8× avg).
Summary
Inovio priced a $75M underwritten offering at $1.05 per share — 28% below the $1.45 last sale — issuing 58.7M shares plus pre-funded warrants for 12.7M more, with net proceeds of about $70M extending cash runway into late Q4 2027.
Key Events · Financing and Capital Events · INO
-
Offering Priced at $1.05 Per Share
58,747,235 shares of common stock at $1.05 and pre-funded warrants for 12,681,337 shares at $1.049, for gross proceeds of $74,987,319.26. The price is 28% below the $1.45 last reported sale on November 5, 2026.
-
Net Proceeds of About $70M
After $4,499,239.16 in underwriting discounts and roughly $535,000 of expenses, Inovio nets about $70.0M, or about $80.5M if underwriters exercise the 30-day option for up to 10,714,285 additional shares.
-
Heavy Dilution to Existing Holders
The offering adds 58.7M shares plus 12.7M pre-funded warrant shares against 110,181,507 shares outstanding as of September 30, 2026. New investors face immediate dilution of $0.47 per share versus pro forma as adjusted net tangible book value of $0.58.
-
Runway Extended to Late Q4 2027
Management states the net proceeds plus current cash and short-term investments of about $48.4M fund operating expenses and capital expenditures into the late fourth quarter of 2027, versus prior guidance of late Q1 2027.
Analysis · INO · Life Sciences
Inovio finalized the underwritten offering it launched November 5, raising roughly $70.0M net (about $80.5M if the over-allotment is exercised) to fund the VOCERYQ launch that won FDA accelerated approval on October 30. The $1.05 share price sits 28% below the $1.45 last reported sale on November 5, so the company conceded meaningful ground to get the deal done — consistent with the going-concern doubt and thin cash position disclosed in the filing. Existing holders absorb heavy dilution: 58.7M new shares plus pre-funded warrants for 12.7M more against 110.2M shares outstanding as of September 30, and new buyers are already $0.47 underwater on net tangible book value at the offering price. The offset is runway: management now says proceeds plus existing cash fund operations into late Q4 2027, versus the prior guidance of late Q1 2027.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.6M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.